U.S. Pharma Stock News

NYSE:SNDA
NYSE:SNDAHealthcare

Evaluating Sonida Senior Living (SNDA) Valuation After Strong 1 Year Return And Premium P/S Multiple

Why Sonida Senior Living Is On Investors’ Radar Sonida Senior Living (SNDA) has drawn attention after recent share price swings, with a 1 day return of 4.34% contrasting with a 4.28% decline over the past week. This has prompted closer portfolio reviews. See our latest analysis for Sonida Senior Living. That sharp 1 day share price return of 4.34% comes after a softer 7 day share price return of 4.28%. Sonida Senior Living still has a 90 day share price return of 13.06% and a 1 year total...
NasdaqGS:LGN
NasdaqGS:LGNConstruction

Assessing Legence (LGN) Valuation After Recent Share Price Momentum And Revenue Growth Expectations

Event context and recent price performance Legence (LGN) has been on many investors’ screens after recent share price moves, with the stock up around 1% over the past week but showing a loss over the past month. See our latest analysis for Legence. Looking past the recent 5.1% 30 day share price return decline, Legence’s 90 day share price return of 22% and year to date gain of 13.9% suggest that momentum has been building from a higher base around the current US$50.90 share price. If...
NasdaqGS:ACAD
NasdaqGS:ACADBiotechs

Has ACADIA Pharmaceuticals (ACAD) Pullback Opened A New Opportunity For Investors?

If you are wondering whether ACADIA Pharmaceuticals at around US$20.61 is offering good value or just fresh risk, you are in the right place for a closer look at what that price might represent. The share price has seen a 7% decline over the last week, an 8.3% decline over the last month, but a 17.8% return over the last year. This can leave investors questioning whether recent weakness is a setback or a reset after earlier gains. Recent attention on ACADIA has centered on its product...
NYSE:ANF
NYSE:ANFSpecialty Retail

Does Record 2025 Results And Margin Guidance Change The Bull Case For Abercrombie & Fitch (ANF)?

In early March 2026, Abercrombie & Fitch Co. reported past fourth-quarter and full-year 2025 results with record sales of US$1,669.8 million and US$5,266.29 million respectively, even as net income eased to US$172.13 million for the quarter and US$506.92 million for the year, alongside ongoing share repurchases and new store expansion plans. The company coupled this performance with 2026 guidance targeting low single-digit net sales growth, double-digit operating margins of about 12.0% to...
NYSE:NCLH
NYSE:NCLHHospitality

Norwegian Luna Launch Tests Norwegian Cruise Line’s Growth And Valuation Story

Norwegian Cruise Line Holdings (NYSE:NCLH) has introduced its next-generation ship, Norwegian Luna, expanding its fleet with new onboard experiences and itineraries. The ship features updated entertainment, dining concepts, and family-focused amenities, along with itineraries that highlight destinations such as Great Stirrup Cay. This launch reflects a significant product refresh aimed at broadening the guest base, including multi generational families. Norwegian Cruise Line Holdings,...
NasdaqCM:PLSE
NasdaqCM:PLSEMedical Equipment

Is Pulse Biosciences (PLSE) Pricing Make Sense After Recent Volatility And DCF Estimate Gap

If you are wondering whether Pulse Biosciences at around US$21.57 offers good value or is running ahead of itself, you are not alone. The stock has seen mixed recent moves, with an 18.9% return over the last 7 days, a 14.6% decline over the past 30 days, a 61.1% return year to date and a 27.6% return over the past year, while the 3 year return is very large and the 5 year return sits at an 8.5% decline. These moves have come against a backdrop of ongoing attention on Pulse Biosciences and...
NYSE:EMN
NYSE:EMNChemicals

Eastman Chemical 2026 Self Help Plan Puts Cost Cuts And Cash First

Eastman Chemical (NYSE:EMN) has rolled out a new 2026 self help plan focused on deeper cost reductions and operational efficiency. The plan also targets expanded capital returns, signaling an intention to keep shareholder payouts in focus alongside internal improvements. Management is positioning the initiative as a material shift in how the company runs its business and allocates cash over the next few years. Eastman Chemical is launching this plan at a time when the stock has faced mixed...
NYSE:MTDR
NYSE:MTDROil and Gas

A Look At Matador Resources (MTDR) Valuation After BMO Outperform Call And Insider Share Purchase

Matador Resources (MTDR) is back on investors’ radar after BMO Capital reaffirmed its positive view on the stock, citing core acreage quality, operational execution, production trends, and recent balance sheet moves. See our latest analysis for Matador Resources. The 1-month share price return of 17.77% and 90-day share price return of 29.11% suggest momentum has been building. The 5-year total shareholder return of 152.21% points to meaningful longer term value creation for investors who...
NasdaqGS:HIMX
NasdaqGS:HIMXSemiconductor

Is It Too Late To Consider Himax Technologies (HIMX) After Recent 33% Weekly Surge?

If you are wondering whether Himax Technologies at around US$9.84 still offers value or if the easy gains are gone, this article unpacks what the current price might be implying. The stock has posted returns of 33.0% over the last 7 days, 19.3% over 30 days, 15.4% year to date and 14.9% over 1 year, with a 3 year return of 46.0% and 5 year return of 1.7% that give important context for any valuation discussion. Recent coverage has focused on Himax's role as a semiconductor player in display...
NYSE:TRU
NYSE:TRUProfessional Services

Assessing TransUnion (TRU) Valuation After Recent Share Price Volatility

Why TransUnion Is Back on Investors’ Radar TransUnion (TRU) has drawn fresh attention after a recent swing in its share performance, with the stock showing a 0.5% gain over the past day but a 9.6% decline over the past week. This short term volatility comes against a backdrop of mixed returns, including a 2.5% decline over the past month and a 17.4% decline over the past 3 months. This may prompt investors to reassess the company’s fundamentals. See our latest analysis for TransUnion. At...
NYSE:HIG
NYSE:HIGInsurance

Is Hartford (HIG) Offering An Opportunity After Recent Share Price Pullback And Strong Multi Year Gains

If you are wondering whether Hartford Insurance Group's current share price still reflects good value, this article walks through what the numbers actually say rather than relying on headlines or hype. The stock last closed at US$132.93, with a 4.5% decline over the past week and a 6.4% decline over the past month, while the 1 year return stands at 13.7% and the 3 and 5 year returns are 114.1% and 117.3% respectively. Recent coverage around Hartford Insurance Group has focused on the company...
NYSE:VIA
NYSE:VIASoftware

Via Transit Wins Highlight Undervalued Growth Story In Public Transport Digitisation

Via Transportation (NYSE:VIA) reports material improvements in city transit performance in the City of Mobile, including better reliability and staffing outcomes without additional budget. The company expands its work with Transport for West Midlands in the UK, adding Citymapper integration to support future regional transit planning. These developments highlight Via’s growing role as a partner for large scale public transit transformation across multiple geographies. Via Transportation,...
NYSE:MCY
NYSE:MCYInsurance

California Driving Law Shifts Reframe Mercury General Risk And Return Profile

California has introduced new driving laws affecting ignition interlock devices, penalties for intoxication related vehicular manslaughter, and rules for autonomous vehicles and electric motorcycles. Mercury General (NYSE:MCY), through its Mercury Insurance brand, has highlighted these legal updates for policyholders and investors. The company views the changes as relevant for risk assessment, claims patterns, and driver behavior in its core California market. For Mercury General, which...
NasdaqGM:MVIS
NasdaqGM:MVISElectronic

MicroVision (MVIS) Is Down 7.0% After Revenue Drop And Narrower Losses In 2025 Results

MicroVision, Inc. has reported its full-year 2025 results, with sales of US$1.21 million compared to US$4.70 million in 2024 and a net loss of US$94.98 million versus US$96.92 million, while basic loss per share from continuing operations narrowed to US$0.35 from US$0.46. The combination of falling revenue and a slightly smaller loss highlights the company’s challenge of scaling its business while still tightly managing costs. With sales declining year over year but net loss narrowing, we’ll...
NYSE:ORA
NYSE:ORARenewable Energy

Is It Too Late To Consider Ormat Technologies (ORA) After 54% One Year Share Price Jump

If you are wondering whether Ormat Technologies' current share price lines up with its underlying value, this article will walk you through the numbers in a straightforward way. The stock closed at US$110.38, with returns of 1.4% over 7 days, a 10.4% decline over 30 days, a 2.9% decline year to date, and a 54.4% return over 1 year, alongside 3 year and 5 year returns of 39.8% and 49.7% respectively. Recent coverage has focused on Ormat Technologies as a long standing player in the US...
NYSE:DAL
NYSE:DALAirlines

Is Delta Air Lines (DAL) Pricing Reflect Recent Pullback And Reassessment Of US Airlines

If you are wondering whether Delta Air Lines is priced attractively right now, this article walks through what the current share price might imply about its underlying value. The stock last closed at US$58.78, with a 7 day return of 0.4% decline, a 30 day return of 17.7% decline, a year to date return of 14.9% decline, a 1 year return of 27.3%, and a 3 year return of 83.8%. Recent coverage around Delta has focused on how investors are reassessing major US airlines as a group, including...
NasdaqGM:ARDX
NasdaqGM:ARDXBiotechs

Will Ardelyx’s (ARDX) IBSRELA Data Shift Its Competitive Position In IBS-C Treatments?

Ardelyx recently reported the peer-reviewed publication of pooled clinical data showing its IBSRELA (tenapanor) therapy delivered earlier and sustained symptom relief in adults with IBS-C, with no new safety concerns identified. The analysis offers clinicians practical guidance on treatment duration and symptom timelines, potentially influencing how IBSRELA is positioned and used in everyday care. We’ll now examine how this new evidence of earlier and sustained IBS-C symptom relief could...
NYSE:SR
NYSE:SRGas Utilities

Spire’s US$11.2 Billion Decade-Long Investment Plan Might Change The Case For Investing In Spire (SR)

Zacks Equity Research recently highlighted Spire Inc.’s long-term infrastructure and innovation plans, including an expected US$11.20 billion in capital investments over the next decade, alongside its current 3.59% dividend yield and analyst estimates for long-term earnings growth. The analysis underscores how these planned investments and anticipated earnings expansion could influence Spire’s role in a gas utility sector balancing aging infrastructure, renewable competition, and the...
NYSE:MUX
NYSE:MUXMetals and Mining

McEwen Mining (MUX) Q4 Profit Jump Challenges Bearish Valuation Narratives

McEwen (MUX) closed out FY 2025 with Q4 revenue of US$64.6 million and basic EPS of US$0.70, alongside net income of US$38.1 million, putting a clear marker on its latest financial run rate. Over the year, quarterly revenue ranged from US$35.7 million in Q1 to US$64.6 million in Q4, while basic EPS moved between a loss of US$0.12 and a gain of US$0.70, giving investors a wide view of how profitability has tracked against the top line. Overall, the results point to firmer margins in the latest...
NYSE:CLVT
NYSE:CLVTProfessional Services

Clarivate Claude Tie Up Tests AI Disintermediation And Workflow Stickiness

Clarivate (NYSE:CLVT) has integrated its regulatory intelligence with Anthropic's Claude AI assistant. The collaboration embeds Clarivate's regulatory data directly into biopharma, biotech, and medtech AI workflows. The move is aimed at supporting regulatory affairs teams by keeping trusted data closer to day to day decision making. Clarivate focuses on data, analytics, and workflow tools for research driven industries, and life sciences is a core part of that mix. By plugging its...
NYSE:CNH
NYSE:CNHMachinery

CNH Industrial Eyes Stickier Revenue With New Antenna And Dealer Expansion

Hemisphere GNSS, a brand of CNH Industrial, has introduced the A65 GNSS antenna in partnership with Calian Group, targeting better interference rejection and easier upgrades for precision agriculture systems. Forrester Farm Equipment is acquiring AG-Industrial, expanding the CNH dealer network and deepening cooperation on parts and service support across North America. CNH Industrial (NYSE:CNH), trading at about $10.65, has a mixed recent performance, with a 13.9% return year to date but...
NYSE:TOL
NYSE:TOLConsumer Durables

Is It Time To Reassess Toll Brothers (TOL) After Recent Share Price Pullback?

If you are wondering whether Toll Brothers is still reasonably priced after a strong run, you are not alone. The stock’s current valuation is a key question for many investors right now. The share price closed at US$136.69, with a 7.4% decline over the last 7 days and a 15.3% decline over the last 30 days, while the 1 year return sits at 31.4% and the 3 year and 5 year returns are 143.5% and 165.4% respectively. Recent news flow around Toll Brothers has focused on broader housing market...
NYSE:INGM
NYSE:INGMElectronic

The Bull Case For Ingram Micro Holding (INGM) Could Change Following Equity Sale And New Buyback Plan

In the past week, Ingram Micro Holding Corporation completed a US$200.00 million follow-on equity offering of 8,988,764 common shares at US$22.25 each, while also announcing a new US$100.00 million share repurchase program tied to secondary offerings by existing shareholders. This combination of fresh equity issuance, a major sell-down by Platinum Equity LLC, and a buyback authorization highlights a significant reshaping of Ingram Micro’s shareholder base without directly changing its...
NYSE:ATO
NYSE:ATOGas Utilities

A Look At Atmos Energy (ATO) Valuation As Infrastructure Spending Accelerates Under Lower Interest Rates

Infrastructure build out becomes the key story for Atmos Energy Atmos Energy (ATO) is ramping up its infrastructure program, with US$3.6b allocated in fiscal 2025 and a planned US$4.2b in 2026, supported by lower interest rates that ease financing costs. See our latest analysis for Atmos Energy. The stock’s recent move appears to reflect investors reacting to this heavier infrastructure spend, with a 7.17% 1 month share price return and a 28.61% 1 year total shareholder return suggesting...